Jw Therapeutics 药明巨诺

Jw Therapeutics 药明巨诺 company information, Employees & Contact Information

Updated June 2026

Quick answer

Jw Therapeutics 药明巨诺 is a Biotechnology company and founded in 2016. It has approximately 107 employees on record. Contact data was last refreshed in June 2026. Find Jw Therapeutics 药明巨诺's verified employee emails, phone numbers, headquarters address, and key decision makers below.

JW Therapeutics is an innovative biotech company focusing on the latest clinical cell therapy technology. It is commited to the development, transformation and promotion of breakthrough cell-based immunotherapies to save the lives of cancer patients, improve their quality of life and bring new hope. JW Therapeutics was co-founded by WuXi AppTec, Juno Therapeutics in February 2016.

Company Details

Employees
107
Founded
2016
Address
浦东新区金科路4560号金创大厦3号楼2层, 上海,上海 201210,china
Phone
+ 86-21-50464201
Industry
Biotechnology
Keywords
Manager jobs.
HQ
上海, 上海
Looking for a particular Jw Therapeutics 药明巨诺 employee's phone or email?

Jw Therapeutics 药明巨诺 Questions

News

JW Therapeutics’ Relma-Cell Approved in China for R/R Mantle Cell Lymphoma - CGTLive®

JW Therapeutics’ Relma-Cell Approved in China for R/R Mantle Cell Lymphoma CGTLive®

Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX - PR Newswire

Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX PR Newswire

JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China - Business Wire

JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China Business Wire

JW Therapeutics rakes in $300M Hong Kong IPO to bring CAR-Ts to China - Fierce Biotech

JW Therapeutics rakes in $300M Hong Kong IPO to bring CAR-Ts to China Fierce Biotech

JW Therapeutics launches $300M IPO in Hong Kong, targets first CAR T approval in China - BioWorld MedTech

JW Therapeutics launches $300M IPO in Hong Kong, targets first CAR T approval in China BioWorld MedTech

JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug - Labiotech.eu

JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug Labiotech.eu

JW Therapeutics Announces New Phase 2 Trial of Relma-Cel in Large B-cell Lymphoma - CGTLive®

JW Therapeutics Announces New Phase 2 Trial of Relma-Cel in Large B-cell Lymphoma CGTLive®

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma - BioSpace

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma BioSpace

Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies - GlobeNewswire

Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies GlobeNewswire

JW Therapeutics accelerates R&D of T cell-based immunotherapies in China - BioSpectrum Asia

JW Therapeutics accelerates R&D of T cell-based immunotherapies in China BioSpectrum Asia

Bluebird spinout 2seventy bio, JW Therapeutics ink $3M deal for solid tumor cell therapy program - Fierce Biotech

Bluebird spinout 2seventy bio, JW Therapeutics ink $3M deal for solid tumor cell therapy program Fierce Biotech

JW Therapeutics, a China CAR-T biotech formed by Juno and WuXi, gains $90M series A - Fierce Biotech

JW Therapeutics, a China CAR-T biotech formed by Juno and WuXi, gains $90M series A Fierce Biotech

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant